Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director · 10% owner | June 18, 2021 | June 22, 2021 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 09, 2022 | June 10, 2022 |
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Director · 10% owner | June 28, 2021 | June 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 18, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.55 · Expires 2031-06-17 | Direct | 15,000 |
Reported balance
After 2021-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-18 · Grant · Acquired 15,000 · Balance 15,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders.
CRISPR Therapeutics AG
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.70 · Expires 2032-06-09 | Direct | 12,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 12,000 · Balance 12,000 F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders.
Monte Rosa Therapeutics, Inc.
Report date June 28, 2021 · Filed June 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital VI, L.P. | 6,799,115 |
Reported balance
After 2021-06-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-06-28 · Conversion · Acquired 6,515,869 · Balance 6,799,115 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage I, L.P. | 2,097,938 |
Last balance in matching sequence
After 2021-06-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-06-28 · Conversion · Acquired 1,940,043 · Balance 1,940,043 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Row 3 · 2021-06-28 · Purchase · Acquired 157,895 · Balance 2,097,938 F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series A convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-28 · Conversion · Disposed 20,004,280 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-28 · Conversion · Disposed 3,000,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-06-28 · Conversion · Disposed 4,150,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series C convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-06-28 · Conversion · Disposed 2,699,328 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 173,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 11 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,383,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 2,210,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,210,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 602 | $14.00 | $8,428.00 |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,334 F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 19,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 2,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 95,596 | $14.00 | $1,338,344.00 |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,104,045 F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 231,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,008,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 3,100,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,777,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 437,247 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 676,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 18, 2016 Filed Oct 20, 2016 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-16-032074 · doc4.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2026-10-18 F1 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016. Read SEC document |
| October 18, 2016 Filed Dec 23, 2016 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-16-163804 · a4.xml · derivative · entry 20 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 60,000 Underlying: Common Stock · 30,000 shares Expires 2026-10-18 F9 · shares: The option grant reported hereby was made to Thomas Woiwode as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person (the grant of which was previously reported by the Reporting Person) and one-half of the reported securities are held by Mr. Woiwode. Pursuant to the agreements described in footnote (1), the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F10 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016. F9 · derivative.underlying_shares: The option grant reported hereby was made to Thomas Woiwode as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person (the grant of which was previously reported by the Reporting Person) and one-half of the reported securities are held by Mr. Woiwode. Pursuant to the agreements described in footnote (1), the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F9 · ownership.nature: The option grant reported hereby was made to Thomas Woiwode as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person (the grant of which was previously reported by the Reporting Person) and one-half of the reported securities are held by Mr. Woiwode. Pursuant to the agreements described in footnote (1), the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.